Diego Braguglia

VI Partners AG (VI Partners) is an independent venture capital firm founded in 2001. The firm is headquartered in Schwyz, Switzerland.

Edimer Pharmaceuticals, Inc. provides biopharmaceutical products for improving the health and quality of life of families living with XLHED. It has developed EDI200 as a treatment for X-linked Hypohidrotic Ectodermal Dysplasia (XLHED), which is a rare orphan disease that causes symptoms including lack of sweat glands, poor temperature control, respiratory problems, and hair and tooth malformations. The company was founded by Pascal Schneider and Olivier Gaide in 2009 and is headquartered in Cambridge, MA.

iOnctura SA is a pre-clinical stage biopharmaceutical company focused on the research and development of novel immuno-oncology therapeutics for patients fighting cancer. The company was founded in June 2017 and is headquartered in Geneve, Switzerland.

AB2 Bio SA develops and manufactures drugs. The firm's products include Interleukin-18 Binding Protein and Proprietary Assay. The company was founded in 2010 and is headquartered in Lausanne, Switzerland.

Xeltis AG develops medical devices to transform standards of care in heart valve replacement and vascular surgery. It develops fully bio absorbable synthetic heart valves and vascular grafts intended to enable for the first time the spontaneous growth of natural, healthy valves and vessels. Its medical device platform comprises bioabsorbable heart valves and blood vessels, designed to enable Endogenous Tissue Restoration (ETR), the natural restoration of the complex body part they replace upon implantation. The company was founded by Martijn Cox, Laurent Grandidier and Simon P. Hoerstrup in 2006 and is headquartered in Zurich, Switzerland.

Amal Therapeutics SA engages in the development of peptide-based therapeutic cancer vaccines. It offers KISMA, a novel peptide/protein-based immunization technology platform, which is self-adjuvanting and enables the assembly within one chimeric fusion protein of elements essential to generate potent immunity. The company was founded by Madiha Derouazi on September 3, 2012 and is headquartered in Geneva, Switzerland.

CeQur SA develops medical devices for diabetes patients. It offers n insulin delivery device that provides three days of consistent, basal insulin deliver along with on-demand bolus insulin. The company was founded by James L. Peterson in January 2008 and is headquartered in Horw, Switzerland.

Picodrill SA provides micromachining techniques for production of hole structures in glass and dielectric materials. The company was founded by M. Eric Lucien, Jean-Pierre Rosat, and Christian Schmidt on October 5, 2007 and is headquartered in Lausanne, Switzerland.